Research map: The optimal threshold of PD-L1 combined positive score to predict the benefit of PD-1 antibody plus chemotherapy for patients with HER2-negative gastric adenocarcinoma: a meta-analysis

Back to the article

Papers in this map

  1. Measuring inconsistency in meta-analyses · Julian P. T. Higgins · 2003 · 64227 citations · Cited by this paper
  2. Canadian Consensus Recommendations for Predictive Biomarker Testing in Gastric and Gastroesophageal Junction Adenocarcinoma · Christine Brezden‐Masley · 2024 · 8 citations · Cites this paper
  3. HBO1 suppresses anti-tumor immunity of CD8⁺ T Cells in thyroid cancer by recruiting BRD4 to regulate VTCN1 expression · 2026 · Related
  4. RoB 2: a revised tool for assessing risk of bias in randomised trials · Jonathan A C Sterne · 2019 · 33351 citations · Cited by this paper
  5. Comparison of immune checkpoint inhibitors in combination with chemotherapy versus chemotherapy alone in the first-line treatment of advanced gastric cancer patients with low PD-L1 expression: a systematic review and meta-analysis · Yuxin Wang · 2025 · 5 citations · Cites this paper
  6. Conserved minimal CD8 cytotoxic immune-state unit in an IL18R1-associated immune program in hepatocellular carcinoma · 2026 · Related
  7. A basic introduction to fixed-effect and random-effects models for meta-analysis · Michael R. Borenstein · 2010 · 6969 citations · Cited by this paper
  8. PD-1/PD-L1 inhibitors in advanced, unresectable esophageal squamous-cell carcinoma: A meta-analysis of their effects across patient subgroups · Mohammed S. Beshr · 2025 · 5 citations · Cites this paper
  9. Impact of neck nodal yield on immune checkpoint inhibitor outcome after recurrence in head and neck squamous cell carcinoma · 2026 · Related
  10. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial · Yelena Yuriy Janjigian · 2021 · 3119 citations · Cited by this paper
  11. Survival prognosis in advanced HER-2 negative gastric cancer treated with immunochemotherapy: A novel model · Zhiyuan Yao · 2025 · 5 citations · Cites this paper
  12. Preclinical efficacy of iPSC-derived MUC1-targeted CAR-NK cells against esophageal squamous cell carcinoma · 2026 · Related
  13. The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method · Joanna IntHout · 2014 · 2379 citations · Cited by this paper
  14. Bibliometric analysis of tumor marker application in gastric cancer diagnosis from 2019 to 2024 · Zhanat Komekbay · 2025 · 4 citations · Cites this paper
  15. Survival outcomes of conversion curative therapy following atezolizumab–bevacizumab in advanced hepatocellular carcinoma · 2026 · Related
  16. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study · Jong‐Mu Sun · 2021 · 1681 citations · Cited by this paper
  17. Three‐Year Follow‐Up of Neoadjuvant Tislelizumab with Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Revealing Cancer‐Associated Fibroblast Heterogeneity Corresponding to PD‐1 Blockade Efficacy · Yao Lin · 2025 · 4 citations · Cites this paper
  18. Integrative single-cell and multi-omics analysis of ZBTB21-mediated serine metabolism in colorectal cancer: from metabolic reprogramming to immune microenvironment modulation · 2026 · Related
  19. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial · Yoon‐Koo Kang · 2022 · 816 citations · Cited by this paper
  20. Optimization of radiation target volume for locally advanced esophageal cancer in the immunotherapy era · Jianming Zheng · 2024 · 2 citations · Cites this paper
  21. Squeezing Treatment-Induced Metabolic Alterations in Melanoma Cells Are Accompanied by Impaired Cluster of Differentiation 8-Positive T Cell and Natural Killer Cell Antitumor Effector Functions · 2026 · Related
  22. Determinants of Response and Intrinsic Resistance to PD-1 Blockade in Microsatellite Instability–High Gastric Cancer · Minsuk Kwon · 2021 · 252 citations · Cited by this paper
  23. Positivity Rate of PD-L1 Expression and Its Clinical Significance in Vulvar Cancer: A Systematic Review and Meta-Analysis · Stefanos Flindris · 2025 · 1 citation · Cites this paper
  24. Efficacy and safety of anti-PD-1 combined with IFN-α1b with or without anlotinib as the first-line therapy in patients with unresectable advanced melanoma: a real-world cohort study · 2026 · Related
  25. Signatures of tumour immunity distinguish Asian and non-Asian gastric adenocarcinomas · Suling J. Lin · 2014 · 236 citations · Cited by this paper
  26. Cadonilimab combined with trastuzumab and chemotherapy for HER2-positive gastric cancer with bone marrow metastasis and DIC: a case report and literature review · Meijing Chen · 2025 · 1 citation · Cites this paper
  27. Spatially fractionated radiotherapy with PD-L1 blockade achieves superior antitumor efficacy and safety in a preclinical model of peritoneal metastasis · 2026 · Related
  28. Dynamic single-cell mapping unveils Epstein‒Barr virus-imprinted T-cell exhaustion and on-treatment response · Miao‐Zhen Qiu · 2023 · 58 citations · Cited by this paper
  29. Efficacy of First-Line Nivolumab Plus Chemotherapy in Advanced Gastric Cancer Stratified by PD-L1 Expression: A Real-World Comparison · Dae-Ho Choi · 2025 · 1 citation · Cites this paper
  30. Appropriate PD-L1 Cutoff Value for Gastric Cancer Immunotherapy: A Systematic Review and Meta-Analysis · Tong Xie · 2021 · 54 citations · Cited by this paper
  31. Clinical benefit of PD-1 antibody plus chemotherapy in advanced HER2 negative gastric or gastro-oesophageal junction adenocarcinoma according to PD-L1 levels: Post-hoc analysis of RATIONALE-305 and pooled analysis of individual patient-level data · Ming-Yu Lai · 2026 · Cites this paper
  32. Untitled · Cited by this paper
  33. Deeper Analysis to Identify the True Benefit of ICIs Immunotherapy in First-Line Treatment for Non-HER2-Positive/HER2-Negative Advanced or Metastatic Advanced or Metastatic Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJC) · Bowen Zheng · 2025 · Cites this paper
  34. Untitled · Cited by this paper
  35. Prognostic Value of Programmed Cell Death Ligand 1 (PD-L1) Expression in Patients With Papillary Thyroid Carcinoma: A Retrospective Biomarker Study · Dimitra Spyroulia · 2025 · Cites this paper
  36. Untitled · Cited by this paper
  37. Efficacy of first-line immunochemotherapy by PD-L1 in HER2-negative gastric or gastroesophageal junction cancer: A meta-analysis · Tong Xie · 2026 · Cites this paper
  38. Untitled · Cited by this paper
  39. PRKX-mediated stabilization of PD-L1 characterizes an immunosuppressive gastric cancer subtype · Qiyue Wang · 2026 · Cites this paper

Source: OpenAlex (CC0)